{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:05:16Z","timestamp":1779311116832,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40121-024-01068-0","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T07:04:04Z","timestamp":1730531044000},"page":"2649-2662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heartfelt Impact: A Descriptive Analysis of Ceftaroline-Containing Regimens in Endocarditis due to Methicillin-Resistant Staphylococcus aureus"],"prefix":"10.1007","volume":"13","author":[{"given":"Kaylee E.","family":"Caniff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Judd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Goro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Orzol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirna","family":"Eshaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al Musawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"issue":"15","key":"1068_CR1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435\u201386. https:\/\/doi.org\/10.1161\/CIR.0000000000000296.","journal-title":"Circulation"},{"issue":"3","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/23744235.2017.1392039","volume":"50","author":"H Asgeirsson","year":"2018","unstructured":"Asgeirsson H, Thalme A, Weiland O. Staphylococcus aureus bacteraemia and endocarditis\u2014epidemiology and outcome: a review. Infect Dis. 2018;50(3):175\u201392. https:\/\/doi.org\/10.1080\/23744235.2017.1392039.","journal-title":"Infect Dis"},{"issue":"10","key":"1068_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11886-018-1043-2","volume":"20","author":"LL Vincent","year":"2018","unstructured":"Vincent LL, Otto CM. Infective endocarditis: update on epidemiology, outcomes, and management. Curr Cardiol Rep. 2018;20(10):86. https:\/\/doi.org\/10.1007\/s11886-018-1043-2.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"1068_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1080\/21505594.2020.1844418","volume":"11","author":"EJM Raineri","year":"2020","unstructured":"Raineri EJM, Yedavally H, Salvati A, van Dijl JM. Time-resolved analysis of Staphylococcus aureus invading the endothelial barrier. Virulence. 2020;11(1):1623\u201339. https:\/\/doi.org\/10.1080\/21505594.2020.1844418.","journal-title":"Virulence"},{"issue":"2","key":"1068_CR5","doi-asserted-by":"publisher","first-page":"e00041","DOI":"10.1128\/CMR.00041-18","volume":"32","author":"A Galar","year":"2019","unstructured":"Galar A, Weil AA, Dudzinski DM, Mu\u00f1oz P, Siedner MJ. Methicillin-resistant Staphylococcus aureus prosthetic valve endocarditis: pathophysiology, epidemiology, clinical presentation, diagnosis, and management. Clin Microbiol Rev. 2019;32(2):e00041-e118. https:\/\/doi.org\/10.1128\/CMR.00041-18.","journal-title":"Clin Microbiol Rev"},{"key":"1068_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.06.002","author":"K Mitsutake","year":"2024","unstructured":"Mitsutake K, Shinya N, Seki M, et al. Clinical characteristics and analysis of prognostic factors in methicillin-resistant Staphylococcus aureus endocarditis: a retrospective multicenter study in Japan. J Infect Chemother. 2024. https:\/\/doi.org\/10.1016\/j.jiac.2024.06.002.","journal-title":"J Infect Chemother"},{"issue":"3","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"issue":"Suppl_3","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1086\/519470","volume":"45","author":"MH Kollef","year":"2007","unstructured":"Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(Suppl_3):S191\u20135. https:\/\/doi.org\/10.1086\/519470.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1128\/AAC.00307-09","volume":"53","author":"N Patel","year":"2009","unstructured":"Patel N, Lubanski P, Ferro S, et al. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(12):5141\u20134. https:\/\/doi.org\/10.1128\/AAC.00307-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","volume":"30","author":"SJ van Hal","year":"2011","unstructured":"van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-na\u00efve patient\u2014a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30(5):603\u201310. https:\/\/doi.org\/10.1007\/s10096-010-1128-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1068_CR11","doi-asserted-by":"publisher","DOI":"10.4137\/CMRT.S1637","volume":"3","author":"C Duplessis","year":"2011","unstructured":"Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011;3:a2466. https:\/\/doi.org\/10.4137\/CMRT.S1637.","journal-title":"Clin Med Rev Ther"},{"key":"1068_CR12","unstructured":"Allergan USA. Teflaro. 2021. https:\/\/www.rxabbvie.com\/pdf\/teflaro_pi.pdf. Accessed Feb 28, 2023."},{"issue":"5","key":"1068_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS II. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267\u201370. https:\/\/doi.org\/10.1093\/jac\/dks006.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1068_CR14","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.02371-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(5):2541\u20136. https:\/\/doi.org\/10.1128\/AAC.02371-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1068_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","volume":"19","author":"JC Lin","year":"2013","unstructured":"Lin JC, Fierer J, Aung G, et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19(1):42\u20139. https:\/\/doi.org\/10.1007\/s10156-012-0449-9.","journal-title":"J Infect Chemother"},{"issue":"2","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","volume":"4","author":"RA Cosimi","year":"2017","unstructured":"Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review. Open Forum Infect Dis. 2017;4(2):ofx084. https:\/\/doi.org\/10.1093\/ofid\/ofx084.","journal-title":"Open Forum Infect Dis"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","volume":"57","author":"S Arshad","year":"2017","unstructured":"Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017;57:27\u201331. https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"1068_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s15010-019-01304-7","volume":"47","author":"T Bhowmick","year":"2019","unstructured":"Bhowmick T, Liu C, Imp B, Sharma R, Boruchoff SE. Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis. Infection. 2019;47(4):629\u201335. https:\/\/doi.org\/10.1007\/s15010-019-01304-7.","journal-title":"Infection"},{"issue":"5","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","volume":"53","author":"CJ Destache","year":"2019","unstructured":"Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents. 2019;53(5):644\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.014.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","volume":"9","author":"EJ Zasowski","year":"2021","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. 2021;9(3):ofab606. https:\/\/doi.org\/10.1093\/ofid\/ofab606.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/cid\/ciad271","volume":"77","author":"VG Fowler","year":"2023","unstructured":"Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: updating the modified Duke criteria. Clin Infect Dis. 2023;77(4):518\u201326. https:\/\/doi.org\/10.1093\/cid\/ciad271.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"1068_CR23","unstructured":"Performance Standards for Antmicrobial Susceptibility Testing. 34th ed. Clinical and Laboratory Standards Institute (CLSI); 2024."},{"issue":"6","key":"1068_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1086\/665731","volume":"33","author":"V Stevens","year":"2012","unstructured":"Stevens V, Lodise TP, Tsuji B, et al. The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2012;33(6):558\u201364. https:\/\/doi.org\/10.1086\/665731.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"8","key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/CIRCULATIONAHA.109.864488","volume":"121","author":"T Lalani","year":"2010","unstructured":"Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment selection bias. Circulation. 2010;121(8):1005\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.864488.","journal-title":"Circulation"},{"issue":"20","key":"1068_CR27","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1001\/jama.2011.1701","volume":"306","author":"T Kiefer","year":"2011","unstructured":"Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA. 2011;306(20):2239\u201347. https:\/\/doi.org\/10.1001\/jama.2011.1701.","journal-title":"JAMA"},{"issue":"10","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1128\/AAC.00797-12","volume":"56","author":"WE Rose","year":"2012","unstructured":"Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother. 2012;56(10):5296\u2013302. https:\/\/doi.org\/10.1128\/AAC.00797-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(1):66\u201373. https:\/\/doi.org\/10.1128\/AAC.01586-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","volume":"7","author":"EK McCreary","year":"2019","unstructured":"McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2019;7(1):ofz538. https:\/\/doi.org\/10.1093\/ofid\/ofz538.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","volume":"9","author":"O Ahmad","year":"2020","unstructured":"Ahmad O, Crawford TN, Myint T. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged Methicillin-resistant Staphylococcus Aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther. 2020;9(1):77\u201387. https:\/\/doi.org\/10.1007\/s40121-019-00277-2.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1068_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106310","volume":"57","author":"TM Johnson","year":"2021","unstructured":"Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021;57(4): 106310. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106310.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1068_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106735","volume":"61","author":"D Patel","year":"2023","unstructured":"Patel D, Brown ML, Edwards S, Oster RA, Stripling J. Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Int J Antimicrob Agents. 2023;61(3): 106735. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106735.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1068_CR34","doi-asserted-by":"publisher","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","volume":"63","author":"M Geriak","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483-e2518. https:\/\/doi.org\/10.1128\/AAC.02483-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_4","key":"1068_CR35","doi-asserted-by":"publisher","first-page":"iv67","DOI":"10.1093\/jac\/dkq256","volume":"65","author":"ML Corrado","year":"2010","unstructured":"Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase\u00a0III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl_4):iv67\u201371. https:\/\/doi.org\/10.1093\/jac\/dkq256.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl_3","key":"1068_CR36","doi-asserted-by":"publisher","first-page":"iii53","DOI":"10.1093\/jac\/dkr099","volume":"66","author":"DR Rank","year":"2011","unstructured":"Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase\u00a0III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl_3):iii53\u20139. https:\/\/doi.org\/10.1093\/jac\/dkr099.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1068_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/1120009X.2017.1296916","volume":"29","author":"BM Ritchie","year":"2017","unstructured":"Ritchie BM, Hirning BA, Stevens CA, Cohen SA, DeGrado JR. Risk factors for acute kidney injury associated with the treatment of bacterial endocarditis at a tertiary academic medical center. J Chemother. 2017;29(5):292\u20138. https:\/\/doi.org\/10.1080\/1120009X.2017.1296916.","journal-title":"J Chemother"},{"key":"1068_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/IDR.S423004","volume":"17","author":"M Kempf","year":"2024","unstructured":"Kempf M, Arhin FF, Kuraieva A, Utt E. In vitro activity of ceftaroline against isolates of gram-positive bacteria from patients with bloodstream infections collected as a part of ATLAS between 2017 and 2020. Infect Drug Resist. 2024;17:343\u201354. https:\/\/doi.org\/10.2147\/IDR.S423004.","journal-title":"Infect Drug Resist"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01068-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:09:33Z","timestamp":1732201773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01068-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01068-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kaylee E. Caniff, Chloe Judd, Kristen Lucas, Sandra Goro, Caroline Orzol, Mirna Eshaya. Mohammed Al Musawa. and Michael P. Veve have no conflicts of interest to report. Michael J. Rybak is a consultant and has received grant funding from Abbvie and has received grant funding from Merck & Co. Michael J. Rybak is an Editor-in-Chief of <i>Infectious Diseases and Therapy<\/i> and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Approval for this study was obtained from the Henry Ford Healthcare Institutional Review Board (#16481-01) and the Wayne State University Institutional Review Board (#22-11-5172) with Detroit Medical Center research authorization. This study received a waiver for the requirement of patient consent given the retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}